Cargando…
Plumbagin is a NF-κB-inducing kinase inhibitor with dual anabolic and antiresorptive effects that prevents menopausal-related osteoporosis in mice
Osteoporosis is caused by enhanced bone resorption and relatively reduced bone formation. There is an unmet need to develop new agents with both antiresorptive and anabolic effects to treat osteoporosis, although drugs with either effect alone are available. A small molecular compound, plumbagin, wa...
Autores principales: | Shen, Gengyang, Liu, Xin, Lei, Wei, Duan, Rong, Yao, Zhenqiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958545/ https://www.ncbi.nlm.nih.gov/pubmed/35235833 http://dx.doi.org/10.1016/j.jbc.2022.101767 |
Ejemplares similares
-
Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy
por: Leder, Benjamin Z
Publicado: (2018) -
Analysis of Serum Proteome after Treatment of Osteoporosis with Anabolic or Antiresorptive Drugs
por: del Real, Alvaro, et al.
Publicado: (2022) -
Combination therapy of anabolic and nonbisphosphonates antiresorptive agents for the treatment of osteoporosis: A meta-analysis
por: Lou, Shenghan, et al.
Publicado: (2017) -
Antiresorptive Versus Anabolic Therapy in Managing Osteoporosis in People with Type 1 and Type 2 Diabetes
por: Vilaca, Tatiane, et al.
Publicado: (2023) -
Anabolic and Antiresorptive Osteoporosis Treatment: Trends, Costs, and Sequence in a Commercially Insured Population, 2003–2021
por: Wadhwa, Harsh, et al.
Publicado: (2023)